NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

Journal article published in 2022 by T. A. Yap, N. Ngoi, E. E. Dumbrava, D. D. Karp, J. Rodon Ahnert , S. Fu, D. S. Hong, A. Naing, S. Pant, S. A. Piha-Paul, V. Subbiah, A. M. Tsimberidou, D. Dufner, J. Rhudy, S. Gore and other authors. T. A. Yap, N. Ngoi, E. E. Dumbrava, D. D. Karp, J. Rodon Ahnert , S. Fu, D. S. Hong, A. Naing, S. Pant, S. A. Piha-Paul, V. Subbiah, A. M. Tsimberidou, D. Dufner, J. Rhudy, S. Gore, S. P. Ivy, Y. Yuan, S. N. Westin, G. B. Mills, F. Meric-Bernstam

Show less

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by